AU2001270381B2 - Streptococcus antigens - Google Patents

Streptococcus antigens Download PDF

Info

Publication number
AU2001270381B2
AU2001270381B2 AU2001270381A AU2001270381A AU2001270381B2 AU 2001270381 B2 AU2001270381 B2 AU 2001270381B2 AU 2001270381 A AU2001270381 A AU 2001270381A AU 2001270381 A AU2001270381 A AU 2001270381A AU 2001270381 B2 AU2001270381 B2 AU 2001270381B2
Authority
AU
Australia
Prior art keywords
polypeptide
seq
bvh
amino acid
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001270381A
Other languages
English (en)
Other versions
AU2001270381A1 (en
Inventor
Bernard Brodeur
Nathalie Charland
Josee Hamel
Denis Martin
Catherine Ouellet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
ID Biomedical Corp of Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ID Biomedical Corp of Quebec filed Critical ID Biomedical Corp of Quebec
Publication of AU2001270381A1 publication Critical patent/AU2001270381A1/en
Assigned to ID BIOMEDICAL CORPORATION reassignment ID BIOMEDICAL CORPORATION Request for Assignment Assignors: SHIRE BIOCHEM INC.
Application granted granted Critical
Publication of AU2001270381B2 publication Critical patent/AU2001270381B2/en
Priority to AU2007207883A priority Critical patent/AU2007207883A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001270381A 2000-06-20 2001-06-19 Streptococcus antigens Ceased AU2001270381B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007207883A AU2007207883A1 (en) 2000-06-20 2007-08-16 Streptococcus antigens

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21268300P 2000-06-20 2000-06-20
US60/212,683 2000-06-20
PCT/CA2001/000908 WO2001098334A2 (en) 2000-06-20 2001-06-19 Streptococcus antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007207883A Division AU2007207883A1 (en) 2000-06-20 2007-08-16 Streptococcus antigens

Publications (2)

Publication Number Publication Date
AU2001270381A1 AU2001270381A1 (en) 2002-03-21
AU2001270381B2 true AU2001270381B2 (en) 2007-05-24

Family

ID=22792041

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001270381A Ceased AU2001270381B2 (en) 2000-06-20 2001-06-19 Streptococcus antigens
AU7038101A Withdrawn AU7038101A (en) 2000-06-20 2001-06-19 Streptococcus antigens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU7038101A Withdrawn AU7038101A (en) 2000-06-20 2001-06-19 Streptococcus antigens

Country Status (18)

Country Link
EP (2) EP2281891A3 (enExample)
JP (2) JP5051959B2 (enExample)
KR (1) KR100927767B1 (enExample)
CN (2) CN1449446A (enExample)
AR (1) AR033980A1 (enExample)
AU (2) AU2001270381B2 (enExample)
CA (1) CA2413450C (enExample)
CZ (1) CZ2003154A3 (enExample)
EA (1) EA006232B1 (enExample)
HU (1) HU228706B1 (enExample)
IL (2) IL153558A0 (enExample)
MX (1) MXPA03000103A (enExample)
NO (1) NO331103B1 (enExample)
NZ (1) NZ553554A (enExample)
PL (1) PL214229B1 (enExample)
TR (1) TR200704553T2 (enExample)
UY (1) UY26783A1 (enExample)
WO (1) WO2001098334A2 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
EP1456231A2 (en) 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN101802198B (zh) * 2007-07-23 2016-02-17 圣诺菲·帕斯图尔有限公司 免疫原性多肽和单克隆抗体
US20120164178A1 (en) 2008-04-16 2012-06-28 Ballou Jr William Ripley Vaccine
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
DK2473605T3 (en) 2009-09-03 2018-05-28 Pfizer Vaccines Llc PCSK9-VACCINE
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
KR101272351B1 (ko) 2010-04-23 2013-06-07 이화여자대학교 산학협력단 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SI3096783T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
KR20210032013A (ko) 2014-01-21 2021-03-23 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
CA2939416A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
EP3244917B1 (en) 2015-01-15 2023-04-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
KR20240169144A (ko) 2017-01-31 2024-12-02 머크 샤프 앤드 돔 엘엘씨 다당류-단백질 접합체 제조 방법
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
KR102701633B1 (ko) 2017-02-24 2024-09-02 머크 샤프 앤드 돔 엘엘씨 폐렴구균 접합체 백신 제제
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112020004509A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
BR112020011414B8 (pt) 2017-12-06 2023-01-31 Merck Sharp & Dohme Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
PH12022550110A1 (en) 2019-07-31 2022-12-12 Sk Bioscience Co Ltd Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
MX2022010355A (es) 2020-02-21 2022-09-21 Pfizer Purificacion de sacaridos.
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
EP4237428A2 (en) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230175284A (ko) 2021-05-28 2023-12-29 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
IL316477A (en) 2022-05-11 2024-12-01 Pfizer Process for producing vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121038808A (zh) 2023-03-30 2025-11-28 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
PE20252779A1 (es) 2023-04-14 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
GEAP202616883A (en) 2023-05-18 2026-03-25 Merck Sharp & Dohme Llc Compounds and adjuvant formulations useful in pneumococcal vaccines
EP4713008A2 (en) 2023-05-19 2026-03-25 GlaxoSmithKline Biologicals S.A. Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025106603A1 (en) 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
KR19990007777A (ko) * 1995-06-07 1999-01-25 듀크두플레시스 면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법
AU9510598A (en) * 1997-09-24 1999-04-12 American Cyanamid Company Human complement c3-degrading proteinase from (streptococcus pneumoniae)
EP1100921B1 (en) * 1998-07-27 2007-05-02 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
CN1263510C (zh) * 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
BR9914066A (pt) * 1998-09-24 2002-04-23 Univ Minnesota Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
DE69940439D1 (de) * 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
KR100802198B1 (ko) * 1998-12-23 2008-02-11 샤이어 바이오켐 인코포레이티드 신규한 스트렙토코커스 항원

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Infection and Immunity 68 (Feb 2000) pp796-800. *
Infection and Immunity 68 (June 2000) pp3740-43 *
J inf Dis 182 (December 2000) 1694-701 *

Also Published As

Publication number Publication date
UY26783A1 (es) 2002-01-31
PL214229B1 (pl) 2013-07-31
EP1303612A2 (en) 2003-04-23
NO20026121L (no) 2003-02-13
TR200704553T2 (tr) 2007-11-21
JP5051959B2 (ja) 2012-10-17
NO20026121D0 (no) 2002-12-19
WO2001098334A3 (en) 2002-09-06
EP2281891A3 (en) 2011-08-17
EP2281891A2 (en) 2011-02-09
HUP0301656A3 (en) 2004-10-28
CN1449446A (zh) 2003-10-15
CZ2003154A3 (cs) 2003-06-18
IL153558A (en) 2011-07-31
CN101260149A (zh) 2008-09-10
HUP0301656A2 (hu) 2003-08-28
CA2413450A1 (en) 2001-12-27
EA006232B1 (ru) 2005-10-27
AR033980A1 (es) 2004-01-21
CA2413450C (en) 2014-02-18
AU7038101A (en) 2002-01-02
EA200201280A1 (ru) 2003-06-26
KR100927767B1 (ko) 2009-11-20
MXPA03000103A (es) 2003-06-19
PL360413A1 (en) 2004-09-06
NZ553554A (en) 2008-11-28
IL153558A0 (en) 2003-07-06
KR20030013450A (ko) 2003-02-14
NO331103B1 (no) 2011-10-10
WO2001098334A2 (en) 2001-12-27
JP2012187110A (ja) 2012-10-04
JP5889103B2 (ja) 2016-03-22
CN101260149B (zh) 2016-05-11
JP2004501618A (ja) 2004-01-22
HU228706B1 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
CA2413450C (en) Streptococcus antigens
US7262024B2 (en) Streptococcus antigens
KR101078919B1 (ko) 신규한 스트렙토코커스 항원
KR100771148B1 (ko) 그룹 ｂ 스트렙토코커스 항원
AU2001270381A1 (en) Streptococcus antigens
US20080038268A1 (en) Streptococcus Pyogenes Antigens
US7074415B2 (en) Streptococcus antigens
AU2008229967B2 (en) Novel streptococcus antigens
AU2001272270B2 (en) Streptococcus pyogenes antigen
AU2007200130B2 (en) Group B Streptococcus Antigens
AU2010227084B2 (en) Group B Streptococcus Antigens
EP1950302B1 (en) Streptococcus antigens
CA2424433A1 (en) Bvh-a2 and bvh-a3 antigens of group b streptococcus
AU2007207883A1 (en) Streptococcus antigens
WO2004007725A1 (en) Polypeptide of streptococcus pyogenes
AU2001272270A1 (en) Streptococcus pyogenes antigen
HK1118575B (en) Streptococcus antigens

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ID BIOMEDICAL CORPORATION

Free format text: FORMER APPLICANT(S): SHIRE BIOCHEM INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired